Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPVN06 Safety and Tolerability in Rod Cone Dystrophy
2022-501250-12-01Phase 2Authorised
- Sponsor
- SparingVision
- Start
- Mar 2023
- Modality
- Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of SPVN06 in retinitis pigmentosa (RP) and Fundus dystrophy, sponsored by SparingVision. Primary endpoint: Safety and tolerability of SPVN06. Planned start Mar 2023; status: authorised.
02
Drugs
SPVN06
03
Conditions
retinitis pigmentosa (RP)Fundus dystrophy
Beyond the preview
Go deeper on 2022-501250-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501250-12-01.